$heff's $tation of $tocks & $olid DD

[rocketeer357]

TCON

Bought a full position of TCON at $6.50. MC of $79 million, 12.2 million O/S

Company has traded to a high of $18.35 in the past year and now sits at the lower end of the 52 week low of $5.88

-Lots of approved drugs to pair in trials with TRC105, TCON's key Endoglin Antibody

-Partnered with Santen in wet AMD ($10 million upfront payment, potentiallly $155 million in milestone payments)
- Strong collaboration with the National Cancer Institute

From the Q1 update:

Three data presentations at the American Society of Clinical Oncology Annual Meeting in June:
Survival data stratified by tumor endoglin expression from the Phase 1b/2 study of the combination of TRC105 and Votrient in soft tissue sarcoma patients, including in an expanded cohort of patients with angiosarcoma.
Overall survival data from the Phase 2 study of the combination of TRC105 and Avastin in Avastin-refractory glioblastoma patients.
Data from the Phase 1 study of the combination of TRC102 and Temodar in refractory solid tumor patients.
- See more at: www.publicnow.com/view/2D364BAD689BB7AC5FA396C1E2A1E4E7395CC6B4#sthash.FJl5kudP.dpuf

'We continue to achieve important clinical progress across our pipeline, and remain on track to initiate our first Phase 3 pivotal study of TRC105 later this year,' said Charles P. Theuer, M.D., Ph.D., President and CEO of TRACON. 'This should be a transformative year for TRACON, as we expect to deliver on a number of key milestones, including multiple Phase 2 data readouts across several indications. - See more at: www.publicnow.com/view/2D364BAD689BB7AC5FA396C1E2A1E4E7395CC6B4#sthash.FJl5kudP.dpuf

$45 million in the bank, ($10 million in debt) which CEO states should see them through all of the P2 trials in 2016.

TCON saw a nice pop in the PPS after ASCO 2105.

I strongly recommend listening to the CEO presentation on May 23, 2016 at the UBS Global Healthcare Conference.

http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-calendar